MedTrace Logo

Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia

NCT00265382 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 221

Last updated 2021-03-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and tolerability of ziprasidone during long-term open-label administration in adolescents (ages 13-17) with schizophrenia.

Conditions

Interventions

DRUG

Ziprasidone oral capsules

Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States
  • Colombia
  • Costa Rica
  • India
  • Malaysia
  • Peru
  • Russia
  • Singapore
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00265382 on ClinicalTrials.gov